Senate roll call 103 · 119th Congress, session 2 · Apr 23, 2026, 2:51 AM ET

On the Amendment S.Amdt. 5336 to S.Con.Res. 33 (No short title on file)

Wyden Amdt. No. 5336

Official result: Amendment Rejected (Amendment Rejected (48-50)) · Required majority: 1/2 · On the Amendment

What was voted on

S.Con.Res. 33 · Vote on an amendment (S.Amdt. 5336), not on final passage of the bill.

Amendment purpose: To establish a deficit-neutral reserve fund relating to requiring the Comptroller General of the United States to conduct a study related to economic consequences of private or confidential drug pricing agreements struck by any Federal department, agency, or office with any pharmaceutical manufacturer.

Recorded choices

Grouped by party as printed on the vote record. Green ✓ yes, orange ✕ no, ringed ○ present, dashed – not voting. Tap a circle to see who it is; pinch or double-tap to zoom.

Official totals

Yea	48
Nay	50
Present	0
Not Voting	2

✓ Individual records add up to the official totals.

Members by recorded choice

Nay 50

Source

Official XML record · Senate.gov vote page

Source last modified: Apr 29, 2026, 7:19 PM ET · First detected by ChamberLens: Oct 20, 2026, 9:43 PM ET · Source last checked: 17 h ago